BMBenjamin Marks

Benjamin Marks

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benjamin Marks has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perturbation biology links temporal protein changes to drug responses in a melanoma cell line

    by Elin Nyman, Richard R. Stein, Xiaohong Jing, Weiqing Wang, Benjamin Marks, Ioannis K. Zervantonakis, Anil Korkut, Nicholas P. Gauthier, Chris Sander

    Cancer cells have genetic alterations that often directly affect intracellular protein signaling processes allowing them to bypass control mechanisms for cell death, growth and division. Cancer drugs targeting these alterations often work initially, but resistance is common. Combinations of targeted drugs may overcome or prevent resistance, but their selection requires context-specific knowledge of signaling pathways including complex interactions such as feedback loops and crosstalk. To infer quantitative pathway models, we collected a rich dataset on a melanoma cell line: Following perturbation with 54 drug combinations, we measured 124 (phospho-)protein levels and phenotypic response (cell growth, apoptosis) in a time series from 10 minutes to 67 hours. From these data, we trained time-resolved mathematical models that capture molecular interactions and the coupling of molecular levels to cellular phenotype, which in turn reveal the main direct or indirect molecular responses to each drug. Systematic model simulations identified novel combinations of drugs predicted to reduce the survival of melanoma cells, with partial experimental verification. This particular application of perturbation biology demonstrates the potential impact of combining time-resolved data with modeling for the discovery of new combinations of cancer drugs. Data-driven mathematical modeling of biological systems has enormous potential to understand and predict the interplay between molecular and phenotypic response to perturbation, and provides a rational approach to the nomination of therapy. In cancer, intense effort has focused on drugs that specifically target the machinery involved in tumor development, maintenance and response to therapy. Although many drugs have clinical efficacy in a fraction of patients, the response is rarely durable and patients often develop resistance within months. We believe that the robustness and complexity of living cells, as well as inaccurate assumptions about drug specificity in model systems, underlie the inadequacy of single-agent targeted therapy. In this work, we developed a framework to derive mathematical models of biological systems from molecular and phenotypic temporal responses, and test this framework on melanoma cells. These models are computationally executable and can be used to predict drug combinations likely to be effective at slowing growth or killing cancer cells. Our framework has several advantages: (1) drug specificity is learned, not assumed, during model training, (2) training on temporal (not static) response data improves predictive power, (3) data-driven dynamic models have the potential to accurately reflect a cellular system’s behavior in a context-specific manner.